|
|
|
|
|
03/2009
American Journal of Physical Medicine and Rehabilitation
PAIN MANAGEMENT WITH OPIOID ANALGESICS: BALANCING RISK AND BENEFIT
(Continuing Medical Education Monograph)
|
Course Objectives
|
|
|
At the conclusion of this activity, participants should be able to:
1. Apply a rational approach to selecting appropriate patients for chronic opioid analgesic therapy;
2. Optimize the therapeutic response through opioid selection, titration, rotation, conversion, and dose tapering;
3. Assess patient outcomes in the domains of analgesia, activities of daily living, adverse effects, and aberrant drug-related behavior;
4. Identify at least one method to use in their practices that will aid documentation when prescribing controlled substances.
|
|
|
|
top
|
|
|
To Receive A Certificate
|
|
|
|
Review the material in the Course Presentations section.
|
|
|
|
Complete the CME Posttest with a score of 7 out of 10 questions correct.
|
|
|
|
You will then be asked to register and complete a brief course evaluation.
|
|
|
|
A certificate will be automatically generated for you online.
|
|
|
|
|
|
|
|
Target Audience
|
|
|
|
This activity is intended for physiatrists who treat patients with chronic pain.
|
|
|
|
top
|
|
|
|
|
Method of Participation
|
|
|
To receive continuing education credit, learners must:
- Read the article in its entirety.
- Take the CE self-assessment test and complete the evaluation.
Please note: The learner must answer at least 70% of the questions on the post-test correctly.
Your continuing education certificate can be printed by following the directions online after successful completion of the post-test and evaluation.
|
|
|
|
top
|
|
|
|
|
Accreditation
|
|
|
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Nebraska Medical Center, Center for Continuing Education (UNMC CCE) and PharmaCom Group, Inc.
The UNMC CCE is accredited by the ACCME to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
|
|
|
|
top
|
|
|
|
|
|
|
Disclosure
|
|
|
Publication of this CME activity is supported by an
unrestricted educational grant from Endo Pharmaceuticals
to the University of Nebraska Medical Center, Center for
Continuing Education (UNMC CCE).
In accordance with the ACCME, the UNMC CCE requires
that any person who is in a position to control the
content of a CME activity must disclose all relevant financial
relationships they have with a commercial interest.
ACCORDINGLY
The UNMC CCE staff and PharmaCom Group staff who
were involved in the development of this activity have no
financial relationships with any commercial interests that
are relevant to this activity.
AUTHOR DISCLOSURES
Steven P. Stanos, DO, reports that he has the following relationships: Consultant for Abbott, Endo Pharmaceuticals, Pfizer, Alpharma Pharmaceuticals, and OrthoMcNeil; and Grants/Research Support from Abbott Labs.
David A. Fishbain, MD, reports that he has no affiliation or financial relationships with any corporate organization
having a direct interest in this activity.
Scott M. Fishman, MD, reports that he has the following relationships: Consultant for Cephalon Inc, Elan Co.,
Endo Pharmaceuticals, Janssen Medical Affairs, LLC,
Merck & Co., Inc, Pfizer Inc, Purdue Pharma L.P., and Eli
Lilly and Company; Speakers' Bureau for Elan Co, Endo
Pharmaceuticals, Janssen Medical Affairs, LLC, Merck &
Co., Inc, Pfizer Inc, and Purdue Pharma L.P.; and Grants/
Research Support from Elan Co, Endo Pharmaceuticals,
Janssen Medical Affairs, LLC, Merck & Co., Inc, Pfizer Inc,
and Purdue Pharma L.P.
RESOLUTION OF CONFLICT OF INTEREST
To resolve identified conflicts of interest, the educational
content was fully peer reviewed by a physician member
of the University of Nebraska Medical Center. The
resulting certified activity was found to provide educational
content that is current, evidence-based, and commercially
balanced.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of
published and/or investigational uses of agents that are not
indicated by the United States Food and Drug Administration.
The University of Nebraska Medical Center, Pharma-
Com Group, Inc, The Association of Academic Physiatrists,
or Lippincott Williams & Wilkins do not recommend the
use of any agent outside of the labeled indications.
|
|
|
|
top
|
|
|
|
|
Disclaimer
|
|
|
|
The content and views presented in this educational
activity are those of the authors and do not necessarily
reflect the views of UNMC CCE, PharmaCom Group, Inc,
The Association of Academic Physiatrists, or Lippincott
Williams & Wilkins. This material is prepared based upon
a review of multiple sources of information, but it is not
exhaustive of the subject matter. Therefore, health care
professionals and other individuals should review and consider
other publications and materials on the subject matter
before relying solely upon the information contained in
this educational activity. The reader is also urged to consult
the full prescribing information on any drug mentioned
in this publication for recommended dosage, indications, contraindications,
warnings, precautions, and adverse effects before
prescribing any medication. This is particularly important when
a drug is new or infrequently prescribed.
|
|
|
|
top
|
|
|
|
|
|
|
